Full Press Release Details
announces results of Annual General Meeting of Shareholders
the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology
company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its annual
general meeting of shareholders held yesterday.
All items on the agenda received a majority of
votes in favor except for agenda item 3 (advisory non-binding vote on the 2022 remuneration report).
As part of the approved resolutions:
The voting result and all documents relating to
the shareholders' meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.
a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading
academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class
portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and- only approved neonatal Fc receptor
(FcRn) blocker in the U.S., the EU and UK, and Japan. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and
advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit https://www.argenx.com/
For further information, please contact: